trial natriuretic factor (ANF) is a cardiac hormone that exhibits potent diuretic, natriuretic, vasorelaxant, and renin-and aldosterone-inhibiting effects and appears to play an important role in the regulation of body fluid volume and blood pressure.1,2 This hormone is typically released from the heart in response to atrial stretch,3-5 although several studies have revealed that plasma levels of ANF in vivo can also be increased by vasoconstrictor agents such as phenylephrine, vasopressin, epinephrine, and angiotensin II (Ang II).6-8 These latter findings would suggest that humoral factors might also regulate ANF release via direct stimulation of atrial tissue. Those studies are not -conclusive, however, since any stimulatory effect that might occur cannot be separated from the hemodynamic actions of those agents, and therefore increased ANF release might simply be the consequence of increased atrial distension. In fact, earlier studies performed both in experimental animals and in humans9 -12 suggested that the hemodynamic changes could entirely account for the increased secretion of ANF associated with Ang II infusion. On the other hand, recent studies by Volpe and coworkers13 showed that systemic infusions of low doses of Ang II stimulated ANF secretion in dogs in the setting of controlled volume expansion and minimal hemodynamic changes. Furthermore, recent studies by Volpe et al '4 showed that Ang II is able to specifically promote ANF release in the rabbit, even when its pressor action is prevented by the concomitant administration of sodium nitroprusside.
The present study was designed to determine whether Ang II has a direct stimulatory effect on cardiac ANF secretion, independent of changes in hemodynamics. The effects of this hormone on ANF release were studied in isolated Langendorff-perfused rabbit hearts in which heart rate, coronary flow, and atrial and ventricular volumes were kept constant.
Methods

Isolated Heart Preparation
Female New Zealand White rabbits (body weight, 1.5-2.0 kg) were anticoagulated with heparin (1 ml i.p.) and anesthetized with sodium pentobarbital (30 mg/kg i.p.). The chest was opened and the heart was rapidly isolated, with care taken to avoid excision of atrial tissue. The aorta was cannulated, and retrograde per-fusion was started by means of a constant-flow roller pump (Masterflex, Cole-Parmer Instrument Co., Chicago, Ill.). The perfusate was a modified Krebs-Ringer bicarbonate buffer containing (in mM) sodium chloride 117, calcium chloride 3.0, EDTA 0.5, magnesium sulfate 1.0, sodium bicarbonate 24.0, potassium chloride 6.0, and glucose 16.7, pH 7.4. The buffer was maintained at 370C and equilibrated with 95%O 2/5% CO2, and it was not recirculated. The flow rate was adjusted to the metabolic needs of each heart so that an initial perfusion pressure of 80 mm Hg could be obtained. Coronary flow was then kept constant throughout the experiment. The coronary circulation perfused the atrial myocardium, which then drained into the general effluent. Venous flow from the coronary sinus drained outside through the pulmonary artery by way of the right atrium and right ventricle. In addition, the atria freely emptied outside the heart through the venae cavae and pulmonary veins, which were cut free. Thus, both atria were in an empty, flaccid state throughout the experiment. Cardiac venous effluent was collected at selected time points to measure coronary flow rates and to quantify ANF release. Effluent samples were collected by drip from the entire heart to include also the fraction of the venous flow that does not drain into the coronary sinus. Parallel experiments (n =4) were performed to determine the hemodynamic stability of the experimental preparation and to evaluate the spontaneous release of ANF from the heart. For this purpose, after 20 minutes of stabilization, hemodynamic parameters were measured, and effluent samples were collected at 10-minute intervals during administration of vehicle alone for 80 minutes.
At the end of the experiment, the heart was removed, the aorta and the pulmonary artery were dissected, and the heart was blotted and weighed.
Radioimmunoassay for Atrial Natriuretic Peptide
The concentration of ANF in the samples from coronary effluent was measured by radioimmunoassay as previously described,'4 using rabbit antiserum (RAS 8798, Peninsula Laboratories), iodinated human ANF (2,000 Ci/mmol, Amersham, Arlington Heights, Ill.), and human ANF-(99-126) (Bissendorf Peptide GmbH, FRG) as a standard. A 100% cross-reactivity with the rat 28-residue peptide has been shown for the antibody used in our assay. In addition, the rat ANF sequence is identical to that of rabbit ANF.15ANF was extracted from the perfusate by use of C-18 cartridges (Millipore, Milford, Mass.). The peptide retained on C-18 was eluted by means of 80% aqueous CH3CN. The lyophilized eluates were reconstituted in radioimmunoassay buffer (phosphate buffer 0.1 M, pH 7.4). Bound/free separation was carried out with 1.5% charcoal-dextran. Nonspecific binding was about 4%. Recoveries determined from each sample by adding to it a small amount of radiolabeled ANF ranged from 59% to 85%. Intraassay and interassay coefficients were 6.6% and 10.5%, respectively. The radioimmunoassay sensitivity was 3 pg per tube. The concentrations of ANF were corrected for the coronary flow, and ANF release was expressed as pg* minm g wet weight`'. consecutive infusions, since baseline levels progressively tended to increase (Figure 1, panel A) .
LV developed pressure, indexed as the difference between LV systolic pressure and LV end-diastolic pressure, also increased in a dose-dependent manner during Ang II infusion in all hearts. However, the effects of Ang II on contractility subsided upon discontinuation of drug infusion (Figure 1, panel B) .
LV end-diastolic pressure showed a progressive increase over the experimental period (p=0.0001 by ANOVA). However, selected contrasts between the values of LV end-diastolic pressure for each dose of Ang II and the corresponding baseline did not show statistical significance (Figure 1 , panel C).
Isolated rabbit hearts showed a sustained release of ANF under control conditions, with marked variations among individual hearts ( Figure 2 ). ANF release in unstimulated hearts progressively decreased during perfusion (p=0.002 by ANOVA) (Figure 2, left panel) .
In the hearts that were to be infused with Ang II, basal release of ANF in the perfusate also tended to decrease during the 30-minute equilibration period: mean values were 1,516+285 pmol . min1 . g`1 at 10 minutes, 1,631±385 pmol . min' g'l at 20 minutes, and 1,311+229 pmol * minm ' g`at 30 minutes (p=NS).
A large variability in ANF release among individual hearts was also observed with respect to the effects of Ang II. Absolute ANF responses to Ang II in individual animals are shown in Figure 2 , right panel. Ang II infusion was followed by a transient increase in ANF release that subsided upon discontinuation of the drug infusion. This phenomenon was observed in seven of nine hearts. ANOVA showed significant variation of ANF release in this group (F=2.79, p=0.03). Selected contrasts of ANF concentrations for each dose of Ang II showed significant differences with the correspondent baseline for 10`10 and 10`M (both p<0.05). Figure 3 depicts the mean percent changes of ANF levels at each time point in the control group (left panel) and at each Ang II dose (right panel). It is evident that Ang II exerted a notable influence on ANF release from the perfused hearts, because increases rather than decreases were observed. ANF released in the perfusate significantly increased in the group of 10 hearts during a single intracoronary infusion of 10`10 M Ang II and returned to baseline after a 10-minute washout period ( Table 2) . Discussion
In the present study, infusion of Ang II significantly increased cardiac release of ANF. Since our experiments were performed on isolated perfused hearts, in which heart rate, coronary flow, and atrial and LV volumes were kept constant and other neural and humoral influences could be eliminated, this finding demonstrates that Ang II can directly stimulate cardiac release of ANF independently of its effects on hemodynamics. Previous animal'0'2 and human9 studies have reported increased plasma levels of ANF during infusion of Ang II in vivo. However, Ang II administration was constantly associated with marked hemodynamic changes, suggesting that increased ANF secretion might have occurred as a consequence of changes in atrial distension, i.e., through a hemodynamic mechanism, rather than through direct receptor stimulation. In fact, changes in plasma ANF in rats infused with several vasoconstrictors, including arginine vasopressin and Ang II, correlated with changes in right atrial pressure2
or systemic blood pressure.812
The effects of Ang II on ANF secretion in an experimental model that allowed control of hemodynamic influences have been previously evaluated by Dietz,"1 who observed no stimulatory effects on ANF secretion in a rat heart-lung preparation. One explanation for the divergent results with respect to the present study may relate to the experimental models. Recent studies have documented that ANF released into the right atrium can be removed or degraded as it passes through the lungs, at least in humans.'7"18 If this mechanism were also operating in rats, it might obscure an increase in ANF secretion in the heart-lung preparation. Similarly, the lack of stimulation of ANF release reported by Lachance and Garcia'2 in atrial slices incubated in the presence of Ang II might be ascribed to the fact that the process of tissue mincing might expose and/or release endogenous peptidases, which may inactivate any excess ANF produced.
Our during the stabilization phase, and there was also a tendency for ANF concentrations in the cardiac effluent to decrease with each consecutive washout period. We believe that this progressive decrease in ANF release is not a sign of deterioration of the preparation, because control hearts proved to be hemodynamically stable throughout the 80-minute observation period. On the other hand, the increased ANF levels measured in the cardiac effluent after Ang II infusions were not the result of fluctuations over baseline, but they were temporally linked to each Ang II infusion.
To further demonstrate the direct relation between Ang II infusion and cardiac ANF release and to eliminate possible artifacts deriving from the approach of gradually increasing the dose of Ang II in the same heart preparation, we performed 10 additional experiments in which a single dose of Ang II was infused to each heart for 5 minutes. We chose 10-Ang II concentration as a single dose to minimize the confounding hemodynamic effects produced by higher doses of the drug. These experiments clearly showed a causal and temporal relation between Ang II infusion and ANF release. Since in the present study we collected the effluent from the entire heart, we cannot exclude that the stimulated release of ANF was at least in part produced by ventricles.
Ang II infusion induced a dose-dependent increase of coronary perfusion pressure, indicating a constrictive effect of Ang II on the coronary arteries. We considered the possibility that the increase in coronary perfusion pressure induced by Ang II affects ANF release. However, the increase in coronary perfusion pressure recorded with the highest dose of Ang II that we used in our experiment (i.e., about 15 mm Hg) is relatively small and is not high enough to exert any metabolic effect, since in our model coronary flow was kept constant. In principle, it is still possible that, although total coronary flow remained constant, relatively small changes in coronary resistances might have affected transmural distribution of flow. We consider this possibility unlikely, on the basis of previous observations from our laboratory,19 which demonstrated that a 30-mm Hg increase in coronary perfusion pressure was not accompanied by detectable changes in transmural perfusion in this experimental model. Furthermore, the increases in ANF release in our experiments were not temporally linked to the increases in coronary perfusion pressure. In fact, Ang II induced a dose-dependent increase of coronary perfusion pressure, which was not reversible during the 10-minute washout period between two consecutive infusions, since baseline levels progressively tended to increase. In contrast, Ang II infusion was followed by a transient increase in ANF release that subsided upon discontinuation of the drug infusion. Thus, ANF release did not increase (and actually decreased) during the intervals between two consecutive Ang II infusions, in spite of the progressive increase in coronary perfusion pressure.
Similarly, we believe that the progressive increase in LV end-diastolic pressure observed in our experiments did not affect ANF release. Although in vivo increase in LV end-diastolic pressure is accompanied by increased distension of both left atrium and ventricle, this phenomenon cannot occur in the isolated Langendorffperfused heart. In fact, 1) in this experimental model, 
